Albany Molecular Research — Merger or Acquisition (May 2016)
21 slides from Albany Molecular Research's merger presentation, May 6, 2016
Slide 1: Acquisition of Euticals Discussion Materials
Acquisition of Euticals Discussion Materials May 5, 2016
Slide 2: Forward-Looking Statements
Forward - Looking Statements This presentation may contain projections, estimates and other forward - looking statements that involve a number of risks and uncertainties, including those discussed in the Company’s filings with the Securities and Exchange Commission. While this presentation represent
Slide 3: Euticals Transaction Summary
Euticals Transaction Summary 2 Euticals • One of the leading players in API in the EU Benefits • Doubles API revenues • Significantly expands EU footprint and customer base Consideration • $358 million in AMRI stock ¹ , seller note and cash Expected Closing • Third quarter of 2016 subject to customa
Slide 4: AMRI is Uniquely Positioned to Capitalize on a Growing Trend in Pharmaceutical Outsourcing
AMRI is Uniquely Positioned to Capitalize on a Growing Trend in Pharmaceutical Outsourcing • Fast - growing contract research, development and manufacturing company serving the brand and generic pharmaceutical markets • Growing portfolio of complex API • Integrating legacy drug discovery expertise w
Slide 5: AMRI is Building a Preeminent Contract Research, Development and Manufacturing Organization
AMRI is Building a Preeminent C ontract Research, Development and Manufacturing Organization for Complex Science Discovery & Development Services (DDS) API Manufacturing Drug Product Manufacturing Sold State Chemistry 2015 API, Drug Product EU Footprint 2015 Commercial Scale Sterile Fill/Finish 2014
Slide 6: Strategic Rationale for Euticals Transaction
Strategic Rationale for Euticals Transaction 5 Elevates AMRI to a leading global player in API Addition of complex assets with high barriers to entry Expands footprint in generics Further growth into Europe Opportunity in fermentation and EU custom synthesis Potential operating, revenue and capital
Slide 7: Euticals Acquisition Elevates AMRI to a Leading Global API Developer and Manufacturer
Euticals Acquisition Elevates AMRI to a Leading Global API Developer and Manufacturer More than doubles API contract revenue 1 • Euticals 2015 total revenue: $245M Significantly expands portfolio of niche, high barrier to entry APIs • Sterile API, steroids, monobactams, boronic acids, controlled sub
Slide 8: Euticals Significantly Diversifies AMRI Geographic Revenue Streams
Euticals Significantly Diversifies AMRI Geographic Revenue Streams 60% 27% 7% 6% Sales US EU 48% 31% 11% 11% Sales RoW Asia EU US 7 Asia RoW AMRI Standalone 2015 Pro Forma 2015
Slide 9: Euticals is a Leading Player in the Pharmaceutical & Fine Chemicals Industry
API MANUFACTURING CUSTOM SYNTHESIS CONTRACT MANUFACTURING FINE CHEMICALS 65% 20% 15% Extensive product portfolio, >200 APIs Global market leadership in many products P rocess development, scale - up, validation and rapid volume escalation N on - GMP to full cGMP synthesis and chemical manufacturing
Slide 10: Euticals 2015 Key Figures
Euticals 2015 Key Figures 9 Extensive Portfolio Over 61 active projects in CS/CMO including 17 CEP granted 400 & 66 EU & US DMF Filed 11 API handled in CS/CMO Qualifications on going 4 Main new launches expected in 2016 More than 70 New Sales More than $244 million t urnover Business 3 Business segm
Slide 11: Euticals Significantly Expands EU Footprint
Hyderabad Singapore Aurangabad Albuquerque, NM Burlington, MA Grafton, WI Glasgow, UK West Lafayette, IN Valladolid Léon San Cristóbal Malta Rensselaer, NY Albany, NY Buffalo, NY Lebanon, NJ Euticals Significantly Expands EU Footprint Adds to AMRI’s Global Service and Product Offering Euticals Exper
Slide 12: Synergies are Financially Compelling
Synergies are Financially Compelling Fully - phased in synergies of $13M to $15M will have a significant impact on EPS and bring EBITDA margins inline with AMRI Expected to be accretive to non - GAAP EPS in 2016 2017 pro forma revenue forecast to exceed $750 million, with adjusted EBITDA margins of
Slide 13: Euticals Transaction Details
Euticals Transaction Details 12 Consideration • $358 million in AMRI stock ¹ , seller note and cash Financing • $63 million seller note • 0.25% annual interest, 5 - year note, amortization in years 3 - 5 Debt Terms • Senior credit facility commitment by JP Morgan and Barclays • Adds $230M to existin
Slide 14: The API Market Environment
The API Market Environment Market Characteristics Global pharmaceutical market to grow from ~ $750 billion in 2014 to almost $1,000 billion by 2020 • Generics are driving volume growth • US is growing by 5% with 88% of prescriptions being filled as generics • Japan is pushing to be at 60% generics b
Slide 15: Targeted Segments for Growth in APIs
Targeted Segments for Growth in APIs √ Controlled Substances • C - II API’s must be manufactured domestically limiting foreign competition • Constant stream of NCEs. Constant reformulation of old opioids (e.g. abuse deterrent forms of “Vicodin ®” • Likely Pathway: Organic Peptides/Proteins • Special
Slide 16: Entering A New Growth Era as Outsourcing Trends Increase
Entering A New Growth Era as Outsourcing Trends Increase Global pharma simplifying to core competencies • Reducing internal resources • Generic competition • Divesting fixed assets • Avoiding technology investments Early to mid - stage companies accessing outsourcing • VCs / Academia / Virtual pharm
Slide 17: Acquisition Supports Goal to Achieve $1B in Revenues in 2018
16 Acquisition Supports Goal to Achieve $1B in Revenues in 2018 $0 $200 $400 $600 $800 $1,000 $1,200 2013 2014 2015 2016E 2017 Pro Forma 2018E $479 > $750 $1,000 $403 $277 $247 DDS API Drug Product Royalties Total 1. 2016E is midpoint of guidance 2. 2017 proforma includes Euticals revenues 3. 2018 g
Slide 18: AMRI Strategy – Disciplined Expansion
17 AMRI Strategy – Disciplined Expansion • Capitalizing on expertise in chemistry • Leverage global recognition in chemistry to build biology • Accelerate growth through attractive partnerships and M&A Discovery & Development Services • Expanding generic portfolio and global footprint • Focusing on
Slide 19: Appendix
Appendix
Slide 20: Appendix A Forward Looking Statements
Appendix A Forward Looking Statements This presentation includes forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws that involve risks and uncertainties. These statements include, but are not limited to, statement
Slide 21: Appendix B
Appendix B The shares of Company common stock (the “Shares”) to be issued in connection with the acquisition of Euticals will be offered and sold outside the United States to Lauro 57, an eligible investor pursuant to Regulation S of the Securities Act of 1933, as amended (the “Securities Act”). The
Albany Molecular Research — Merger or Acquisition (May 2016) on 6ix